Abstract:Mild cognitive impairment (MCI) is the prodromal phase of Alzheimer's disease (AD) and while it presents as an imperative intervention window, it is difficult to detect which subjects convert to AD (cMCI) and which ones remain stable (sMCI). The objective of this work was to investigate fluid-attenuated inversion recovery (FLAIR) MRI biomarkers and their ability to differentiate between sMCI and cMCI subjects in cross-sectional and longitudinal data. Three types of biomarkers were investigated: volume, intensity and texture. Volume biomarkers included total brain volume, cerebrospinal fluid volume (CSF), lateral ventricular volume, white matter lesion volume, subarachnoid CSF, and grey matter (GM) and white matter (WM), all normalized to intracranial volume. The mean intensity, kurtosis, and skewness of the GM and WM made up the intensity features. Texture features quantified homogeneity and microstructural tissue changes of GM and WM regions. Composite indices were also considered, which are biomarkers that represent an aggregate sum (z-score normalization and summation) of all biomarkers. The FLAIR MRI biomarkers successfully identified high-risk subjects as significant differences (p < 0.05) were found between the means of the sMCI and cMCI groups and the rate of change over time for several individual biomarkers as well as the composite indices for both cross-sectional and longitudinal analyses. Classification accuracy and feature importance analysis showed volume biomarkers to be most predictive, however, best performance was obtained when complimenting the volume biomarkers with the intensity and texture features. Using all the biomarkers, accuracy of 86.2 % and 69.2 % was achieved for normal control-AD and sMCI-cMCI classification respectively. Survival analysis demonstrated that the majority of the biomarkers showed a noticeable impact on the AD conversion probability 4 years prior to conversion. Composite indices were the top performers for all analyses including feature importance, classification, and survival analysis. This demonstrated their ability to summarize various dimensions of disease into single-valued metrics. Significant correlation (p < 0.05) with phosphorylated-tau and amyloid-beta CSF biomarkers was found with all the FLAIR biomarkers. The proposed biomarker system is easily attained as FLAIR is routinely acquired, models are not computationally intensive and the results are explainable, thus making this pipeline easily integrated into clinical workflow.

MRA: A multimodal MRI-derived amyloid- biomarker for Alzheimer's disease

MRAβ: A multimodal MRI‐derived amyloid‐β biomarker for Alzheimer's disease

Combining Blood-Based Biomarkers and Structural MRI Measurements to Distinguish Persons with and without Significant Amyloid Plaques

Predicting Brain Amyloid Using Multivariate Morphometry Statistics, Sparse Coding, and Correntropy: Validation in 1,101 Individuals From the ADNI and OASIS Databases

Machine Learning-Derived MRI-Based Neurodegeneration Biomarker for Alzheimer's Disease: A Multi-Database Validation Study

Detecting Amyloid Positivity Using Morphometric Magnetic Resonance Imaging

Comparative analysis of multimodal biomarkers for amyloid-beta positivity detection in Alzheimer's disease cohorts

MRI-based Deep Learning Assessment of Amyloid, Tau, and Neurodegeneration Biomarker Status across the Alzheimer Disease Spectrum

Early Detection of Amyloid Pathology in Alzheimer's Disease by Molecular MRI

Combining PET with MRI to Improve Predictions of Progression from Mild Cognitive Impairment to Alzheimer's Disease: an Exploratory Radiomic Analysis Study

P2‐073: FEASIBILITY OF QUANTIFYING AMYLOID BURDEN USING VOLUMETRIC MRI DATA: PRELIMINARY FINDINGS BASED ON THE DEEP LEARNING 3D CONVOLUTIONAL NEURAL NETWORK APPROACH

Synthesizing beta-amyloid PET images from T1-weighted Structural MRI: A Preliminary Study

Multiparametric hippocampal signatures for early diagnosis of Alzheimer's disease using 18F-FDG PET/MRI Radiomics

Combination of automated brain volumetry on MRI and quantitative tau deposition on THK-5351 PET to support diagnosis of Alzheimer’s disease

Combining PET with MRI to improve predictions of progression from mild cognitive impairment to Alzheimer’s disease: an exploratory radiomic analysis study

Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers

Statistical Parametric Mapping in Amyloid Positron Emission Tomography

Utility of cerebrovascular imaging biomarkers to detect cerebral amyloidosis

Detecting conversion from mild cognitive impairment to Alzheimer's disease using FLAIR MRI biomarkers

Combining Multimodal Neuroimaging Biomarkers in the Diagnosis of Alzheimer’s Disease and Mild Cognitive Impairment

Multimodal MRI Accurately Identifies Amyloid Status in Unbalanced Cohorts in Alzheimer's Disease Continuum